| Literature DB >> 34093138 |
Daniel Eskenazi1,2, Lauren Malave1,2, Susana Mingote1,2,3, Leora Yetnikoff4,5, Samira Ztaou1,2, Vlad Velicu1,2, Stephen Rayport1,2, Nao Chuhma1,2.
Abstract
Discovered just over 20 years ago, dopamine neurons have the ability to cotransmit both dopamine and glutamate. Yet, the functional roles of dopamine neuron glutamate cotransmission and their implications for therapeutic use are just emerging. This review article encompasses the current body of evidence investigating the functions of dopamine neurons of the ventral midbrain that cotransmit glutamate. Since its discovery in dopamine neuron cultures, further work in vivo confirmed dopamine neuron glutamate cotransmission across species. From there, growing interest has led to research related to neural functioning including roles in synaptic signaling, development, and behavior. Functional connectome mapping reveals robust connections in multiple forebrain regions to various cell types, most notably to cholinergic interneurons in both the medial shell of the nucleus accumbens and the lateral dorsal striatum. Glutamate markers in dopamine neurons reach peak levels during embryonic development and increase in response to various toxins, suggesting dopamine neuron glutamate cotransmission may serve neuroprotective roles. Findings from behavioral analyses reveal prominent roles for dopamine neuron glutamate cotransmission in responses to psychostimulants, in positive valence and cognitive systems and for subtle roles in negative valence systems. Insight into dopamine neuron glutamate cotransmission informs the pathophysiology of neuropsychiatric disorders such as addiction, schizophrenia and Parkinson Disease, with therapeutic implications.Entities:
Keywords: Parkinson disease; VGLUT2; VMAT2; addiction; glutaminase; psychostimulant; schizophrenia
Mesh:
Substances:
Year: 2021 PMID: 34093138 PMCID: PMC8170480 DOI: 10.3389/fncir.2021.665386
Source DB: PubMed Journal: Front Neural Circuits ISSN: 1662-5110 Impact factor: 3.492
FIGURE 1DA neuron GLU cotransmission spans phylogeny from flies to humans. The first physiological or anatomical evidence for DA neuron GLU cotransmission is cited by species.
TH and VGluT2 coexpression in midbrain DA neurons.
| TH+VGLUT2+/Total TH+% | |||||||||||
| Age | Species | Genotype | Method | Midbrain (Total) | Medial-only | Lateral-only | Citation | ||||
| E11 | Mouse | WT | ISH | (>E14) | |||||||
| E14 | Mouse | WT | ISH | (<E11) | |||||||
| E14 | Mouse | sc RT-PCR | 7 | ||||||||
| E16 | 47 | ||||||||||
| E18 | 33 | ||||||||||
| E15, 16 | Rat | WT | ISH | (High) | |||||||
| E18, 21 | (Low) | ||||||||||
| P0 | Mouse | dissociation, sc RT-PCR | 25 | ||||||||
| P0 | Mouse | IHC (TH, EGFP) | 2 | ||||||||
| P0-2 | Mouse | sc RT-PCR | 22 | 36 | 13 | ||||||
| P5 | Rat | WT | ISH | 3 | <1 | ||||||
| P10 | Mouse | IHC (TH, EGFP) | 1 | ||||||||
| P10 | Rat | WT | ISH | 2 | <1 | ||||||
| P14 | Mouse | sc RT-PCR | 14 | ||||||||
| P14 | Mouse | sc RT-PCR | 18 | 14 | |||||||
| P15 | Rat | WT | ISH | 2 | <1 | ||||||
| P35 | Mouse | sc RT-PCR | 30 | ||||||||
| P45 | Mouse | dissociation, sc RT-PCR | 14 | ||||||||
| P45 | Mouse | IHC (TH, EGFP) | <1 | ||||||||
| 6–24 weeks | Mouse | WT | ISH (RNA Scope) | 56 | 37 | ||||||
| P70 | Mouse | sc RT-PCR | 47 | 78 | 25 | ||||||
| P90 | Rat | WT | ISH | 2 | <1 | ||||||
| 8–12 weeks | Mouse | ISH | 15 | 20 | |||||||
| Adult | Rat | WT | ISH | <1 | |||||||
| Adult | Rat | WT | ISH | 3 | 22 | ||||||
| 5 | 22 | ||||||||||
| 19 | 53 | ||||||||||
| Adult | Rat | WT | TH-IHC, | 60 | 10 | ||||||
| 50 | 60 | ||||||||||
| Laser micro-dissection, sc RT-PCR | 42 | ||||||||||
| 42 | |||||||||||
| 57 | |||||||||||
| Adult | Marmoset | WT | TH-IHC, | 23 | 2 | <1 | |||||
| 2 | 2 | <1 | |||||||||
| 5 | 3 | <1 | |||||||||
| 6 | 4 | < 1 | |||||||||
| Adult (55 years) | Human | WT | TH-IHC, | 17 | 10 | 2 | |||||
| 2 | 10 | 3 | |||||||||
| 10 | 3 | ||||||||||
| <1 | |||||||||||
FIGURE 2Functional connectome analysis of VTA DA neuron GLU cotransmission. Regions with prominent connections, the NAc m-shell (A), dorsal striatum (B), prefrontal cortex (C), amygdala (D), and hippocampal formation (E) are shown, with the neurons principally targeted by DA-GLU neurons in each region. The strength of connections is indicated by the thickness of the axons (black lines). Postsynaptic neurons are GABAergic (blue), GLUergic (magenta), or cholinergic (green).
FIGURE 3Cotransmission configurations. We define DA neuron GLU cotransmission as the release of DA and GLU from the same neuron. Anatomically, DA and GLU could be released from the same vesicles (labeled as corelease), or from separate sites in the same varicosity, or more distant sites within the same axon (not shown).
FIGURE 4Vesicular synergy. Shown in the left panel, a VMAT2+ SV undergoes (1) vesicular acidification, then (2) VMAT2 exchanges two H+s for DA to achieve (3) baseline vesicular DA concentration and subsequent (4) baseline DA release. Shown in the right panel, a VGLUT2+/VMAT2+ co-expressing SV, (1) VGLUT2 transports GLU and Cl– into SV, which potentiates (2) vacuolar-type H+ATPase to hyperacidify the SV, thus (3) more DA is drawn in via VMAT2 in exchange for protons, resulting in (4) greater intravesicular DA concentration and subsequent release (5).
FIGURE 5DA neuron GLU cotransmission circuit effects. DA neuron GLU cotransmission (1) increases ChI activity (2) and acetylcholine release that activates nAChRs on DA neuron terminals (3) to increase DA release (4). In DA-neuron-specific VGluT2 cKO mice (1) there would be no increase in ChI activity, (2) attenuated activation of nAChRs (3) and reduced DA release (4). Vesicular synergy is not shown in this figure.
Effect of toxins on DA neuron GLU cotransmission.
| Species and Age | Genotype | Method | Toxin | TH+VGLUT2+/Total TH+% | Effect on DA neurons | Citation | |
| VTA | SN | ||||||
| Rat P15 | WT | ISH | 7.1 | 0.7 | In NAc% TH+/VGLUT2+ axon terminals higher in 6-OHDA group (37.4%) | ||
| 26 | 0.0 | ||||||
| Mouse P52 | WT | IHC | 15 | 9.0 | Increased loss of SN TH+ neurons | ||
| 19 | 21 | ||||||
| IHC | − | Increased loss of SN TH+ neurons, significantly more in cKO mice | |||||
| Mouse P8–12 weeks | IHC | − | Increased loss of midbrain TH+ neurons in cKO mice | ||||
| − | Increased loss of midbrain TH+ neurons in cKO mice | ||||||
| Mouse P8–12 weeks | IHC | 15 | 20 | Increased loss of VTA and SN TH+ neurons in cKO mice. Reduced TH and DAT throughout striatum. Viral rescue of | |||
| 35 | 45 | ||||||
| – | – | ||||||
| Mouse > P60 | - | - | Impaired striatal re-innervation post-6-OHDA in cKO mice. | ||||
| Rat P90 | WT | ISH | 2.4 | 0.3 | In NAc% of TH+/VGLUT2+ axon terminals higher with 6-OHDA (0.05%) | ||
| 7.2 | 0.0 | ||||||
Positive valence systems: reward responsiveness construct.
| Paradigm | Manipulation | Behavioral Result | Citation | |
| 20 mg/kg i.p. | ||||
| 10 mg/kg i.p. | ||||
| 20 mg/kg i.p. | Heterologous | |||
| 5 days of daily injections (20 mg/kg i.p) and re-test 72 h later | ||||
| 5 days of daily injections (20 mg/kg i.p.). No re-test | Intact sensitization. However, on day 5, cKO mice had | |||
| Intact sensitization. Though, overall, | ||||
| 1.5, 3.0, and 5.0 mg/kg i.p. | Overall activity of cKO | |||
| 0.75 mg/kg i.p. | ||||
| 1.5 mg/kg i.p. | ||||
| 3.0 and 5.0 mg/kg i.p. | ||||
| 3.0 mg/kg i.p. | Heterologous | |||
| Five daily injections of 2.5 mg/kg i.p. Challenge to same dose 2 weeks later. | ||||
| Four daily injections of 3.0 mg/kg i.p. Challenge to same dose 2 weeks later | ||||
| Both groups showed an increase in AMPH-induced locomotion, | ||||
Motor control systems.
| Paradigm | Manipulation | Behavioral Result | Citation |
| Heterozygous | |||
| MPTP induced a | |||
| MPTP-induced |
Positive valence systems: reward learning construct.
| Paradigm | Manipulation | Behavioral Result | Citation | |
| 5 mg/kg s.c. for 3 days | ||||
| 0.0625, 0.125, and 1.0 mg/kg infusion | ||||
Cognitive control systems.
| Paradigm | Manipulation | Behavioral Result | Citation |
Negative valence systems.
| Paradigm | Manipulation | Behavioral Result | Citation |